| ²é¿´: 235 | »Ø¸´: 1 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
yyatÒø³æ (ÕýʽдÊÖ)
|
[½»Á÷]
Ò»¶ÎÓ¢ÎÄÕªÒª·ÒëÇóÖú ¶àл
|
||
|
Ibuprofen Inhibits Skeletal Muscle Hypertrophy in Rats Abstract Purpose: We sought to determine whether cyclooxygenase (COX) activity is necessary for overload-induced growth of adult rat skeletal muscle, and whether nitric oxide synthase (NOS) activity is involved in upregulation of COX messenger RNA (mRNA) expression in skeletal muscle. Methods: Unilateral surgical removal of the gastrocnemius and soleus was performed on the right hindlimb of 16 female Sprague-Dawley rats (~230 g) to induce chronic overload (OL) of the plantaris for 14 d, with sham surgeries performed on the contralateral leg as a normally loaded (NL) control. Half of the rats were treated with the nonspecific COX inhibitor, ibuprofen (0.2 mg•mL-1 in drinking water; ~20 mg•kg-1•d-1). In a second experiment, the plantaris was unilaterally overloaded for 5 or 14 d in male rats (~350 g; N = 16 rats per time point) and half of the animals were treated with the NOS inhibitor, L-NAME (0.75 mg•mL-1 in drinking water; ~90 mg•kg-1•d-1). Results: Ibuprofen treatment inhibited plantaris hypertrophy by approximately 50% (P < 0.05) following 14 d of OL, as did L-NAME treatment (P < 0.05). COX-1 and COX-2 mRNA did not differ between any groups at 5 d. At 14 d, however, L-NAME caused a 30-fold increase in plantaris COX-1 mRNA expression independent of loading condition. Additionally, OL induced a 20-fold increase in COX-2 mRNA expression compared with NL (P < 0.05) at 14 d, without affecting COX-1 mRNA level. L-NAME treatment significantly inhibited OL-induced expression of COX-2 mRNA. Conclusion: COX activity is important for in vivo muscle hypertrophy, and plantaris overload is associated with NOS activity-dependent COX-2 expression. |
» ²ÂÄãϲ»¶
26µ÷¼Á 086003
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸ÉϺ£º£Ñó´óѧ083200ʳƷѧ˶£¬Çóµ÷¼Á£¬½ÓÊÜÆäËûרҵ083200
ÒѾÓÐ4È˻ظ´
²ÄÁÏ»¯¹¤306·ÖÕÒºÏÊʵ÷¼Á
ÒѾÓÐ4È˻ظ´
292·Ö£¬²ÄÁÏÓ뻯¹¤£¬ÉêÇëµ÷¼Á
ÒѾÓÐ24È˻ظ´
ÊýÒ»Ó¢Ò»274»úеµ÷¼Á
ÒѾÓÐ5È˻ظ´
²ÄÁÏר˶322·Ö
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸°²»Õij211 0703»¯Ñ§×Ü·Ö339Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
±¾9Ò»Ö¾Ô¸2 0854µÍ·Öר˶286Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
ÇóÉúÎïѧרҵµ÷¼Á-332·Ö
ÒѾÓÐ3È˻ظ´
pharmjackie
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 21
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 2210
- Ìû×Ó: 312
- ÔÚÏß: 180.4Сʱ
- ³æºÅ: 302356
- ×¢²á: 2006-12-02
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
yyat(½ð±Ò+10):лл 2010-03-30 08:29
|
ÊÔÒëÈçÏ£º²»ÉõÑϽ÷£¬²»ÉõÕýÈ·£¬ÇëרҵÈËʿָÕý£º ²¼Âå·ÒÔÚÊóÖÐÒÖÖÆ¹Ç÷À¼¡·Ê´ó×÷ÓÃÑо¿ ÕªÒª£ºÎÒÃÇÑо¿ÁË»·ÑõºÏø£¨COX£©µÄ»îÐÔ¶ÔÓÚ³ÉÄêÊó¹Ç÷À¼¡³¬¸ººÉÓÕµ¼µÄµÄÉú³¤ÊÇ·ñ±ØÐ룬һÑõ»¯µªºÏ³Éø(NOS)ÊÇ·ñÔÚCOXµÄmRNAÔÚ¹Ç÷À¼¡±í´ïµÄÉϵ÷Öз¢»Ó×÷Óᣠ·½·¨£º¶Ô16Ö»´ÆÐÔSprague-DawleyÊó£¨Ô¼230¿Ë£©µÄÓÒºóÖ«½øÐе¥²àÊÖÊõÒÆ³ýë賦¼¡ºÍ±ÈÄ¿Ó㼡£¬ÒÔʹÄÚÓÕµ¼õż¡ÂýÐÔ³¬¸ººÉ£¨OL£©14Ì죬¶ÔÆä¶Ô²àÖ«Ìå×÷¼ÙÊÖÊõÒÔ×÷ΪÕý³£¸ººÉµÄ¶ÔÕÕ£¨NL£©¡£°ëÊýÊóʹÓ÷ÇÌØÒìÐÔCOXÒÖÖÆ¼Á£¬²¼Âå·Ò£¨ÓÚÆäÒûË®ÖмÓÈë0.2mg/ml£¬Ô¼20mg/kg.Ì죩¡£ÁíÒ»ÏîʵÑéÖУ¬Ê¹ÐÛÊóõż¡µ¥²à³¬¸ººÉ5»ò14Ì죨Լ350¿Ë£¬Ã¿Ê±¼äµãÑù±¾Êý16Ö»£©£¬ÆäÖаëÊý¶¯ÎïʹÓÃNOS,L-NAME(ÒûË®ÖмÓÈë0.75mg/ml£¬Ô¼90mg/Kg.Ìì¡£ ½á¹û£º14ÌìOLºóʹÓò¼Âå·ÒÖÎÁÆõÅ·ÊÒÖÖÆÂÊ´óÔ¼50%£¨P<0.05)£¬ÓëL-NAMEÏàËÆ£¨P<0.05).Á½×éÔÚµÚ5ÌìʱµÄCOX-1ºÍCOX-2 mRNA²¢Ã»ÓÐÏÔÖø²îÒ졣Ȼ¶øÔÚµÚ14Ììʱ£¬L-NAMEÒýÆðõż¡COX-1 mRNA±í´ïÔö³¤ÁË30±¶£¬ÇÒÓ븺ºÉÎ޹ء£´ËÍ⣬ÓëNLÏà±È£¬ÔÚµÚ14ÌìʱOLÒýÆðCOX-2 mRNA±í´ïÔö³¤20±¶£¨P<0.05)£¬ÇÒûÓÐÓ°ÏìCOX-1 mRNAˮƽ¡£Ê¹ÓÃL-NAMEÖÎÁÆÏÔÖøÒÖÖÆÁËOL-ÓÕµ¼µÄCOX-2 mRNA±í´ï¡£ ½áÂÛ£º COX»îÐÔÔÚÌåÄÚ¹Ç÷À¼¡·Ê´óÖÐÆð×ÅÖØÒª×÷Óá£õż¡³¬¸ººÉÊÇÓëNOS»îÐÔÒÀÀµµÄCOX-2±í´ï¹ØÏµÃÜÇС£ |
2Â¥2010-03-22 19:37:44














»Ø¸´´ËÂ¥